(1) Progressive clinical course with features of HLH (2) Overt infiltrates of CD8+ and CD56 − cytotoxic T-lymphocytes with small or occasionally medium to large-sized or large nuclei (3) Overt lymphoma or rearrangements of T-cell receptor (TCR) genes. This evidence concerns the gene NCAM1 and lymphoma.